Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2023-01-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prehabilitation
Prehabilitation
A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prehabilitation
A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Approval to engage in exercise as per screening by the CSEP or ACSM certified CEP and/or clinician
* Ability to provide written informed consent and understand study information.
Exclusion Criteria
* Diagnosed with acute leukemia but not undergoing work-up for allo-HSCT
* Unable to read/communicate in English (i.e., unable to complete experimental procedures such as patient-reported outcomes).
* Neurological or musculoskeletal comorbidity inhibiting exercise.
* Diagnosed psychotic, addictive, or major cognitive disorders.
* Severe coronary artery disease (Canadian Cardiovascular Society class III or greater).
* Significant congestive heart failure (New York Heart Association class III or greater).
* Severe thrombocytopenia (platelets \<10) - ok if transfused platelets prior to exercise.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alberta Cancer Foundation
OTHER
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicole Culos-Reed, PhD
Role: STUDY_DIRECTOR
Health and Wellness Lab and the Thrive Centre
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACE-HSCT
Identifier Type: -
Identifier Source: org_study_id